56-cessation-database
Asset valuation: $3,000,000,000. AI-Generated Cessation Research Substrate for Pharma R&D Acquisition (Product title updated from earlier working name "Universal Non-Chemical Cessation Alchemy Database". Canonical title is now "Cessation Alchemy Data".)
Think of restoring an old house: the furniture comes last, and the first job is the wiring, the plumbing and the shelves. Cessation Alchemy Data is a research substrate built on that idea. It is non-opioid and non-chemical primary, so it does not ask a buyer to synthesise a new molecule. Instead it maps the systems that addiction and substance-induced psychosis disrupt - neurotransmitter precursors, receptors, brain-critical elements, neuroplasticity, the gut-brain axis and dual-diagnosis stabilisation - and organises them as six Universal Cessation Forces applied across nine substance and dual-diagnosis categories, cross-referenced against ten companion projects from the inventor's health portfolio.
Above that matrix sit eight clinical modules: an objective withdrawal test, a six-panel blood-work protocol, detection windows for nineteen substances, a fourteen-nutrient toxicology reference, precision dosing, non-chemical pain management, a completion-certificate framework and a resolution computation engine. A chart benchmarks eight FDA-approved cessation compounds against the substrate, and seven elemental-repair recipes with G-code bridge straight into the Chemical Cooker. The whole thing is 134 KB of structured JSON.
This is computational research, not medical advice: nothing here has been clinically tested or FDA-approved, and it claims no outcome. It is written for pharmaceutical research teams, digital-therapeutics designers, contract-research trial architects and consumer-health nutrition programs who want one unified starting point where today there are only isolated evidence bases. The buyer walks away with the substrate, the modules and the recipe bridge as a standalone acquisition; the patent-pending IP stays with the inventor at every tier, cited inside as provenance, not as something for sale.
Description
Cessation Alchemy Data — the Alchemical Architecture for Cessation (Project 56, SKU 2087)
Inventor: Christopher Gabriel Brown.
Product full title: Cessation Alchemy Data — the Alchemical Architecture for Cessation (UCF family, 6 forces × 9 protocols).
Project number: 56.
SKU: 2087.
Package identifier: special-56-cessation-database .
Version: 3.1.0 (manifest header 3.0.0; substrate rev 3.1.0).
Publication date: 2026-07-03.
Classification: NON-OPIOID · NON-CHEMICAL PRIMARY · PATENT-PENDING.
Status: Patent-pending. IP fully retained by inventor across every commercial tier. No patent license, IP license, exclusive rights, or ownership transfer conveyed at any tier. Patent numbers cited within the substrate are cited as provenance (proving authorship and priority date), not as items being sold or licensed.
Bundle status: Standalone acquisition. Not included in the All-In-One bundle.
Database size: 134 KB structured JSON ( cessation_pharma_database.json ).
Design-target disclaimer: Computational research findings — not medical advice, not clinically tested, not FDA-approved. Deliverables are R&D substrate for pharma-industry validation and clinical program design.
Overview
Cessation Alchemy Data is a first-of-its-kind AI-generated cessation research substrate assembled by Christopher Gabriel Brown for pharmaceutical R&D acquisition, digital-therapeutics program design, contract-research trial architecture, and consumer-health nutritional-neuroscience programs. It is non-opioid and non-chemical primary : the substrate does not require the buyer to synthesise a new molecule. Instead it targets the endogenous neurotransmitter, receptor, elemental, neuroplastic, gut-microbiome, and dual-diagnosis stabilisation systems that addiction and substance-induced psychosis disrupt.
The organising principle of the substrate is the Universal Cessation Force (UCF) family — six mechanistic forces applied across nine substance and dual-diagnosis categories, cross-referenced against ten companion research projects from the inventor’s health portfolio. Layered above the UCF matrix are eight doctor-grade clinical modules: an objective withdrawal test (the UWI), a six-panel blood-work protocol, detection windows for nineteen substances, a fourteen-nutrient toxicology reference with a drug–nutrient interaction matrix, a precision dosing module, a non-chemical pain management module, a Cessation Completion Certificate framework, and an individualised Resolution Computation Engine. A public-knowledge chemistry-comparison chart benchmarks eight FDA-approved cessation compounds against the UCF substrate. A twenty-five-event historical timeline and ten forward-looking AI-generated predictions anchor the substrate in the trajectory of cessation medicine. A Chemical Cooker (Project 16) recipe bridge ships alongside — seven ready-to-run UCF-4 elemental-repair recipes plus G-code, schema-conformant to the published Cooker recipe schema.
The thesis, in the inventor’s own words: “Time is a prayer. Cessation is time work. Every receptor system heals on a measurable timeline. Every day of abstinence is a physical prayer to the future self you are becoming. The molecules do not know your name. The receptors do not know your story. But they know time. And they answer.”
Why This Substrate Exists
The addiction crisis is a category emergency. The U.S. opioid crisis kills 80,000+ Americans per year (design-target figure from published mortality categories). Global addiction economic burden exceeds USD $600B per year in the U.S. alone (aggregate across healthcare, productivity, and criminal-justice cost centres). Existing cessation pharmacotherapy relies on a handful of aging molecules — varenicline, bupropion, cytisine, naltrexone, acamprosate, disulfiram, lofexidine, NAC — each with modest efficacy and meaningful side-effect profiles. The molecule pipeline is thin. Big pharma has largely exited addiction molecule design.
Non-chemical cessation is the emerging category. Digital therapeutics, nutritional neuroscience, exercise medicine, sleep medicine, and gut-microbiome interventions each carry isolated evidence bases. No one has assembled them into a unified substrate. Cessation Alchemy Data is that assembly. Dual-diagnosis (substance-induced psychosis in LSD, HPPD, cannabis, and stimulant use) is the underserved gap between addiction medicine and psychiatry, and UCF-6 is the substrate for that gap.
The Six Universal Cessation Forces (UCF)
The UCF framework is the organising principle. Six mechanistic forces, each with a distinct mechanism-of-action principle, drive cessation across every substance category. The forces are additive to any existing cessation pharmacotherapy and open novel R&D and product-line pathways.
Force Name Principle Representative Substrate Contents
UCF-1 Neurotransmitter Precursor Restoration Feed the brain the raw materials to rebuild its own chemistry Tyrosine, tryptophan, phenylalanine, choline, glutamine mapped per substance
UCF-2 Endogenous Reward Reactivation Twenty-eight non-chemical activities that generate the same neurotransmitters drugs provide Endorphin, dopamine, serotonin, oxytocin, GABA, and endocannabinoid activity classes with mechanism and evidence citation for each activity
UCF-3 Neural Pathway Rewiring BDNF-driven neuroplasticity acceleration Habit-loop replacement, sleep-architecture restoration, cross-reference to Project 11 (Alzheimer’s) BDNF science
UCF-4 Elemental Brain Repair Precision element restoration per substance Zn, Fe, Cu, Mg, Se, P, S mapped to the twenty brain-critical elements identified in Project 22
UCF-5 Gut-Brain Axis Restoration Ninety percent of serotonin is synthesised in the gut Four-phase remove → repair → reinoculate → rebalance microbiome protocol
UCF-6 Dual-Diagnosis Psychosis + Substance Withdrawal Stabilise substance-induced psychosis alongside withdrawal Sleep, grounding, reality anchor, anti-inflammatory nutrition, glutamate modulation for LSD, HPPD, cannabis, stimulant, and dissociative presentations. No competing framework covers this gap.
Substance and Dual-Diagnosis Coverage (9 Categories)
Full 6-UCF protocols are delivered for nine distinct categories. Each protocol identifies the hijacked receptor system, withdrawal timeline, medical warnings where applicable, and the precise UCF stack.
Category Receptor / Mechanism Target Clinical Notes
Nicotine / Tobacco Nicotinic acetylcholine receptors (nAChR α4β2 primary) Acetylcholine + dopamine restoration; standard cessation drug overlap available
Alcohol GABA-A, NMDA, endorphin systems Severe withdrawal warning included — delirium tremens can be fatal; medical supervision indicated for heavy-use cessation
Opioids Mu-, kappa-, delta-opioid receptors Non-opioid protocol; endorphin + enkephalin + dopamine restoration
Cannabis / Marijuana CB1 and CB2 endocannabinoid receptors Anandamide + 2-AG + dopamine restoration; cognitive testing recommended
Stimulants (cocaine, methamphetamine, amphetamines) DAT (dopamine transporter), dopamine-release mechanism Dopamine + serotonin + norepinephrine restoration; ECG / troponin / echo baseline
LSD / Psilocybin / DMT / Mescaline 5-HT2A, 5-HT1A, 5-HT2C receptors Classical psychedelic cessation stack
HPPD (Hallucinogen Persisting Perception Disorder) Serotonergic dysregulation, cortical hyperexcitability Dedicated protocol; EEG / MRI baseline
Substance-Induced Psychotic Disorder Dual-diagnosis stabilisation UCF-6 stack applied alongside substance-specific UCF-1…5 protocol
Universal Daily Protocol Substrate-agnostic maintenance Sixteen daily protocol items applicable to any substance
Doctor-Grade Clinical Module 1 — UCF Withdrawal Index (UWI)
The single hardest question in recovery is: am I healed yet? Standard cessation medicine has never had an objective answer. The UWI is the test the inventor wished he had. Ten domains, each scored 0–4, total 0–40. Trackable daily during acute withdrawal, weekly during post-acute, monthly during late recovery.
The ten UWI domains are: physical symptoms, sleep, autonomic function, appetite, mood, cognitive function, cravings, anhedonia, social function, and substance-thought autonomy.
Doctor-Grade Clinical Module 2 — Cessation Completion Certificate
Objective criteria for the recovery discharge summary that addiction medicine has lacked. Certificate eligibility requires: UWI ≤4 sustained for thirty days + a negative urine screen + a negative hair screen (ninety-day look-back) + normal blood-work panels + the substance-specific minimum abstinence time. When met, the substrate produces a signed completion milestone — a documented endpoint that recovery culture has historically lacked.
Doctor-Grade Clinical Module 3 — Blood Test + Lab Panel Module (6 Panels)
2 Nutrient Status Vitamin D 25(OH)D, iron studies, B12 / MMA, folate / homocysteine, Mg, Zn, Cu / ceruloplasmin, Se, omega-3 index
3 Neurotransmitter Metabolites 5-HIAA, HVA, VMA, MHPG, salivary cortisol curve, serum BDNF
4 Substance-Specific GGT / CDT / MCV for alcohol; HCV / HIV / testosterone for opioid; ECG / troponin / echo for stimulant; cognitive testing for cannabis; EEG / MRI for HPPD
5 Inflammation + Recovery hsCRP, IL-6, TNF-α, homocysteine
6 Clearance Certification Composite requirements to sign the Cessation Completion Certificate
Doctor-Grade Clinical Module 4 — Drug Testing Reference (19 Substances)
Detection windows across urine, blood, saliva, hair, EtG, and breath for nineteen substance categories. Includes a false-positive avoidance list — poppy seeds → opiate positive; hemp seeds and CBD → THC positive; pseudoephedrine, bupropion, and trazodone → amphetamine positive; kombucha and hand sanitiser → EtG positive — and clearance-test scheduling at 30 / 60 / 90 days of abstinence to support Completion Certificate issuance.
Doctor-Grade Clinical Module 5 — Toxicology Module (14 Nutrients)
Doctor-grade safety reference for every UCF-4 nutrient intervention. Each of the fourteen nutrient entries includes RDA, UL, therapeutic range, toxic threshold, overdose symptoms, contraindications, form bioavailability, drug interactions, and rescue protocols. Values are public-domain from the Institute of Medicine / National Academy of Medicine Dietary Reference Intakes.
A ten-row Drug–Nutrient Interaction Matrix covers critical combinations:
Levothyroxine + iron / calcium / magnesium / zinc Absorption interference; separation timing required
Nine intervention entries with acute-withdrawal dose, maintenance dose, blood-level target, form selection guidance, timing, onset, and duration-of-use. Renal adjustments are eGFR-based and hepatic adjustments are Child-Pugh-based. A baseline lab set is specified for intake plus follow-up intervals: weekly during acute withdrawal, biweekly-to-monthly during stabilisation, quarterly during maintenance.
Doctor-Grade Clinical Module 7 — Pain During Cessation Module
Cessation is a state of high pain. Standard programs fail because pain drives relapse. This module treats pain as the primary clinical challenge, with seven substance-specific pain profiles (mechanism, VAS severity, timeline, clinical-scale reference — CIWA-Ar for alcohol, COWS for opioid, CWS for cannabis) and nineteen non-chemical pain interventions across physical, psychic, and sleep domains. Each intervention specifies mechanism, dose or duration, cost range, and evidence citation.
Doctor-Grade Clinical Module 8 — Resolution Computation Engine
The product does not merely browse — it computes a resolution. The engine converts patient state into an individualised weekly cessation plan.
Days abstinent Precision doses adjusted for renal / hepatic function and medication interactions
Renal / hepatic function Cessation Completion Certificate criteria specific to substance and patient
Pregnancy status Medical escalation red-flag markers, expected receptor recovery timeline, next review date
The Complete tier includes the algorithmic specification of the engine. The buyer implements the engine within their platform (EHR module, DTx application, clinical decision-support surface). The substrate provides the deterministic logic; the buyer provides the software surface.
Chemistry Comparison Chart — Eight FDA-Approved Compounds Benchmarked
Eight FDA-approved cessation compounds are benchmarked side-by-side against the UCF substrate. Each entry includes molecular formula, mechanism class, target substance, design-target efficacy, black-box warnings, typical side effects, cost range, duration, and UCF overlap analysis.
Bupropion (Zyban / Wellbutrin) NDRI + nicotinic antagonist Nicotine + depression UCF-1 + partial UCF-2
Cytisine (Tabex) Natural nicotinic partial agonist Nicotine UCF-1
Naltrexone (ReVia / Vivitrol) Opioid receptor antagonist Alcohol + opioid Different mechanism than any UCF
N-Acetylcysteine (NAC) Glutamate modulator / antioxidant Cannabis, cocaine (research) STRONG — UCF-1 + UCF-4 + UCF-6
Positioning is additive , not competitive: the UCF substrate does not displace existing pharmacotherapy. It occupies the adjacent space — what to do besides the drug, when the drug is contraindicated, or when the drug has failed.
History Timeline (25 Events, 1935–2026)
Twenty-five-event historical timeline from 1935 (AA founding) through 2026 (this substrate). Milestones cited include: nicotine polacrilex (1984), transdermal nicotine patch (1991), naltrexone alcohol indication (1994), bupropion smoking-cessation indication (1997), acamprosate FDA approval (2004), varenicline FDA approval (2006), Vivitrol opioid use disorder indication (2010), reSET digital therapeutic FDA authorisation (2017), lofexidine FDA approval (2018), reSET-O OUD digital therapeutic (2018), psilocybin Phase 2 signals (2020), NAC cannabis-cessation trials (2023), GLP-1 off-label observations (2024), through to Project 56 (2026).
Ten AI-Generated Predictions (5-year and 10-year Horizons)
5-year Psilocybin-assisted therapy receives FDA Breakthrough Therapy status for nicotine and alcohol
Strategic counsel is delivered for the following audience segments: pharma R&D teams, digital-therapeutics builders, CROs and academic researchers, clinicians and addiction-medicine specialists, and inventor-level counsel on pricing, forward compatibility, and category positioning. Five documented failure modes are catalogued so acquirers can steer around them from day one.
Chemical Cooker Compatibility — UCF-4 Recipe Bridge (7 Recipes)
The substrate ships with a Chemical Cooker recipe bridge that converts each UCF-4 Elemental Repair formulation into Chemical Cooker-native recipe JSON plus ready-to-run G-code. A Chemical Cooker owner (Project 16, separately available) can natively load and physically prepare the seven UCF-4 blends. The bridge emits schema-conformant files only — no proprietary Cooker code is imported or copied — and IP for both projects is retained by the inventor across all tiers.
The recipe schema followed is the published 16-chemical-cooker/platform/lite_alchemy/schema.json . Default deck positions (reservoir_1…4, well_1, well_2, waste) are supplied and may be overridden in the Cooker platform config. Compatibility version is 1.0 (2026-07-03).
Companion Research Projects (Separately Available)
The substrate is scaffolded against the inventor’s health-research portfolio. Each companion is a separate acquisition through cri-one.com/store and is not conveyed with Project 56 at any tier.
CEASE-56-RESEARCH Licensed Research $9,997 Read-only document license to read, study, cite, and internally reference the substrate. Full cessation_pharma_database.json (v3.1.0). All documentation (README, BUYER_PITCH, LICENSING, HANDOFF_BLURB, WEB_DESCRIPTION, MANIFEST). Interactive Python query tool. Evidence citation index. Excludes commercialisation rights, derivative-work rights, and inventor consultation. Academic research team, internal R&D screening, single-investigator use
CEASE-56-DESIGN Design Target $499,997 Everything in Licensed Research plus worldwide commercialisation rights for research findings within the acquirer’s cessation program, right to build and publish derived research works, right to license findings into the acquirer’s internal cessation program, and a 60-day email consultation window with the inventor. Excludes patent license, IP ownership, and the right to resell the substrate as a standalone product. Pharma R&D division adding a non-chemical arm to an existing cessation program
CEASE-56-COMPLETE Complete $50,000,000 Everything in Design Target plus twelve-month email + postal consultation, cross-reference index to the ten companion research projects, integration guidance for clinical program design, and pharma-industry outreach & positioning package. USA-based deliverable. Excludes patent license, IP ownership, companion project acquisitions, and clinical-trial services. Pharma / digital-therapeutics acquirer building a differentiated cessation program
Full cessation_pharma_database.json (v3.1.0, 134 KB structured JSON) Any patent license or IP transfer — patents-pending retained by inventor
All documentation (README, BUYER_PITCH, LICENSING, HANDOFF, MANIFEST, WEB_DESCRIPTION) Any right to file continuation patents on the substrate
Interactive Python query tool ( cessation_query.py ) with the Resolution Computation Engine Any Chemical Cooker (Project 16) hardware or platform rights
Chemical Cooker recipe bridge (7 pre-generated recipes + G-code) Any companion project (07, 10, 11, 12, 13, 16, 22, 33, 41, 46) acquisition rights
Evidence citation index Right to represent oneself as the inventor
Store-integration snippets and imagery (SVG symbol, banner, icon) Exclusive rights or ownership transfer
Candidate Acquirer Categories
- Big-pharma cessation and CNS R&D divisions
- Digital therapeutics companies with cessation programs
- Contract research organisations specialising in addiction and CNS trials
- Consumer-health companies with nutritional-neuroscience programs
- Government and foundation research funders (NIH / NIDA-adjacent programs)
- Academic medical centres with addiction research programs
Design-target aggregate market figures from public category estimates; not investment advice.
An interactive Python shell for querying the substrate and running the Resolution Computation Engine.
Interactive commands include anchor , forces , protocol , uwi , blood , drugtest [s] , compute , pain [s] , tox [n] , dose [n] , interactions , chem , history , predictions , counsel , tiers , full , and quit . Example: compute opioids 45 22 returns the individualised weekly UCF stack, precision doses, drug-test schedule, days remaining to Completion Certificate eligibility, and receptor recovery timeline for a patient 45 days into opioid cessation with a UWI of 22 (post-acute severe).
Substrate database cessation_pharma_database.json 134 KB structured JSON (v3.1.0) — the actual deliverable
Query tool cessation_query.py Interactive query shell + Resolution Computation Engine
Documentation — core README.md , MANIFEST.json , HANDOFF_BLURB.md Overview, package manifest, short handoff blurb
Documentation — commercial BUYER_PITCH.md , LICENSING.md , UPLOAD_TO_WEBSTORE.md Pharma acquisition pitch, tier ladder & terms, store-upload checklist
Documentation — web WEB_DESCRIPTION.html , cessation_store_description.html Store-ready HTML product descriptions (short and long grey/black/white)
Chemical Cooker bridge cooker_compat/cessation_ucf_to_recipe.py , cooker_compat/COOKER_COMPATIBILITY.md , cooker_compat/recipes/MANIFEST.json Bridge generator, compatibility documentation, recipe manifest
Chemical Cooker recipes (7) cessation_nicotine_ucf4.{json,gcode} , cessation_alcohol_ucf4.{json,gcode} , cessation_opioid_ucf4.{json,gcode} , cessation_cannabis_ucf4.{json,gcode} , cessation_stimulant_ucf4.{json,gcode} , cessation_psychosis_ucf4.{json,gcode} , cessation_universal_daily_ucf4.{json,gcode} Pre-generated Chemical Cooker recipes + G-code for the seven UCF-4 blends
Store integration cards store_integration/research_card.html , store_integration/health_wellness_card.html , store_integration/all_products_card.html , store_integration/product_summary_block.html , store_integration/STORE_INTEGRATION_NOTES.md Magento CMS page cards for research, health-wellness, and all-products destinations plus reusable summary block and push instructions
Figures — vector figures/cessation_symbol.svg , figures/cessation_icon_256.svg , figures/cessation_store_display.svg Source SVG assets
Figures — raster figures/cessation_symbol.png (512×512), figures/cessation_symbol_256.png (256×256), figures/cessation_symbol_200.png (200×200), figures/cessation_icon.png , figures/cessation_store_display.png (1200×600), figures/cessation_store_display_1000.png (1000×500), figures/cessation_flat_symbol.png , figures/cessation_flat_symbol_200.png , figures/cessation_flat_icon.png Magento-ready product imagery (base, small, thumbnail, icon, hero) — colourful, simple, embedded description + date + copyright
Figure generator figures/generate_pngs.py Pillow-based regenerator; run python figures/generate_pngs.py at any time to rebuild the raster set
Push tool push_to_store.py Store push utility
Inventor reference 1 light trigger.txt , CONTACT_INFO.txt , Contact Information.txt , Yesterday.txt , Tomorrow.txt Inventor IP catalogue reference and contact records
Acquisition Terms
- IP: Retained by inventor across every tier. No patent license, IP license, exclusive rights, or ownership transfer conveyed at any tier.
- Buyers: USA-only. Up to four USA-domiciled entities per transaction (joint & several liability).
- Currency: USD only.
- Contact channels: Email and postal only. No phone. No brokers or intermediaries.
- Governing law: State of Georgia, Gwinnett County.
- Refunds: All sales final and non-refundable.
- Bundle: Standalone acquisition. Not included in the All-In-One bundle.
- Delivery: USA-based, AES-256 encrypted package.
Guardrails Applied Throughout
- Says “patent-pending” — never “patented”.
- Computational research findings — not medical advice, not clinically tested, not FDA-approved.
- Email + postal only; no phone; USA-only; USD only.
- IP retained; no patent license conveyed at any tier.
- No fabricated customer names or adoption claims.
Email and postal only. USA-only. USD only.
How this is delivered
This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.
Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.
© 2026 Christopher Gabriel Brown. All rights reserved. Patent-pending.
All performance figures are design targets, not measured guarantees.
Available exclusively to buyers incorporated, headquartered, and primarily operating in the United States. USD only.
Communication by email and postal mail only — no phone calls, no brokers, no intermediaries.
Photo
Footnotes
- Product number 8506.
- Family: alchemy data.
- Purchase: When you buy, you buy the use of that blueprint only.